Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Fepixnebart (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Acronyms CPMP
- Sponsors Eli Lilly and Company
Most Recent Events
- 10 Dec 2021 Status changed from active, no longer recruiting to completed.
- 15 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2021 Planned End Date changed from 5 May 2022 to 15 Nov 2022.